WASHINGTON, D.C. - When officials at Warner-Lambert Co. discovered they had a potentially life altering diabetes drug in production, they were thrilled. However, new documents show that research quickly showed the drug, Rezulin, caused liver damage.
Executives allegedly continued to promote the drug, which generated $2.1 billion in sales before being taken off the market three years after approval by officials at the Food and Drug Administration (FDA).
The drug was removed from store shelves because many liver-related deaths were linked to its use. New documents show Warner-Lambert executives may have known about this potentially lethal side effect from the beginning, but instead decided to conceal the information.
Pfizer Inc., which has since acquired Warner-Lambert, has turned information over to officials. More than 2,000 lawsuits have been filed for the 5,100 estimated Rezulin users.
Information from www.sfgate.com
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.